Company profile
CYBIN INC.
NASDAQ:HELPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Deupsilocin | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06564818 | phase3 | active_not_recruiting | 2024-12-17 | 2026-08-01 | Cybin IRL Limited | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" |
| NCT06793397 | phase3 | recruiting | 2025-12-10 | 2027-03-18 | Cybin IRL Limited | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder |
| NCT06051721 | phase2 | completed | 2024-05-10 | 2025-10-14 | Cybin IRL Limited | A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) |
| NCT05385783 | phase1_2 | completed | 2022-08-02 | 2023-10-16 | Cybin IRL Limited | A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder |
| NCT05594667 | phase2 | withdrawn | 2023-01-01 | 2023-03-14 | Cybin Therapeutics Inc. | Effect of SSRIs on Response to Psilocybin Therapy |
FDA applications (0)
No records yet.